Bunnage Mark E.

EVP, Chief Scientific OfficerVERTEX PHARMACEUTICALS INC / MA (VRTX) · full profile →Form 4 · filed Feb 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 18, 2026Sell(S)1K$473.68$560K8K
Feb 17, 2026Sell(S)2K$489.46$1.2M10K
Feb 17, 2026Tax withholding(F)1K$483.75$537K12K
Feb 17, 2026Grant(A)3K$013K

Transaction Codes

S
Open-market sale
F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000875320-26-000088) within minutes of acceptance. Every field above traces to the original document. Verify it directly: